NCT03027960View on ClinicalTrials.gov

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 27, 2017

Primary Completion Date

May 14, 2019

Study Completion Date

June 1, 2019

Conditions
Heart FailureType II; Diabetes
Interventions
DRUG

Empagliflozin

10mg empagliflozin for a 2-week period

DRUG

Placebo Oral Capsule

10 mg placebo for a 2-week period

Trial Locations (1)

06511

Yale New Haven Hospital, New Haven

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Yale University

OTHER